91 results about "Xanthine oxidase activity" patented technology

The invention relates to application of celery seed extract to preparation of medicine or health-care food for resisting to hyperuricemia and gout and further provides medicine or health-care food for treating hyperuricemia and gout. Celery seed extract serves as the active constituent, and an appropriate number of medical carriers or auxiliary constituents are added, so that a preparation is obtained. The medicine for health-care food is simple in preparation process, the celery seed extract can obviously lower serum uric acid of model mice suffering from hyperuricemia caused by oteracil potassium salt, lower the activity of xanthine oxidase to different degrees, achieve an obvious inhibition effect on arthritis of the mice, prevent and treat hyperuricemia or gout and be applied to preparation of the medicine or health-care food for resisting to hyperuricemia and gout.

The invention disclosed an aryl nitrile group thiazole derivative for inhibiting the activity of xanthine oxidase, a method for preparing the same and application thereof. In the aryl nitrile group thiazole, R1 is methyl, ethyl, propyl, isopropyl, isobutyl, methyl cyclopropane, methyl cyclobutane, isoamyl, methyl cyclopentane, methyl cyclohexane or aromatic ring methyl, R2 is methyl or trifluoromethyl, and R3 is formic acid, sodium formate, potassium formate, lithium formate, methyl formate, or ethyl formate. Simultaneously, the invention discloses a method for synthesizing the aryl nitrile group thiazole derivative by using inexpensive raw materials, which has the advantages of simple operation, high yield, easy purification of products, application to industrial production and the like, and can obtain an efficient compound with low toxicity through screening; besides, the effective compound is expected to be widely applied to inhibit the activity of the xanthine oxidase required on animals and humans, and to become a new generation of antigout drugs and hyperuricemia drugs with special effect.

The invention discloses a lactobacillus plantarum UA-416 strain and application thereof, and belongs to the field of functional food microbes. Blanks of lactobacillus plantarum in the effects of lowering uric acid and resisting gout are filled up. According to the lactobacillus plantarum (Lactobacillus plantarum) UA-416 strain provided by the invention, the bacterial strain is already collected inthe China Center for Type Culture Collection (CCTCC) on July 25, 2017; the collection number is CCTCC NO: M2017419. The lactobacillus plantarum UA-416 strain provided by the invention can be used foreffectively lowering the level of blood uric acid, is used for improving the levels of urea nitrogen and creatinine and inhibiting the activity of xanthine oxidase in serum, and has prevention and treatment effects on uricemia or the gout.

The invention discloses lactobacillus gasseri and application thereof in relieving and treating hyperuricemia, and belongs to the technical field of microorganisms. According to the lactobacillus gasseri CCFM1133 disclosed by the invention, the serum uric acid level of hyperuricemia mice and the xanthine oxidase (XOD) activity of serum and a liver can be reduced, and the occurrence of hyperuricemia and gout is reduced; the blood glucose and serum triglyceride (TG) level of a patient with hyperuricemia can be regulated, and the activity of liver catalase (CAT) and glutathione peroxidase (GSH-Px) is improved; expression of ileum ABCG2 is improved, and excretion of intestinal uric acid is promoted; and the intestinal short-chain fatty acid level is improved, and the health is promoted. The lactobacillus gasseri CCFM1133 disclosed by the invention can be used for preparing foods, functional foods or medicines, and has a wide application prospect.

The invention discloses lactobacillus rhamnosus NX-2 and an application thereof in preparation of uric acid reducing drugs, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus NX-2 disclosed by the invention has a preservation number of CGMCC No.20110. Non-inactivated and inactivated fermentation supernate, bacterial suspension and cell disruption material supernate of the lactobacillus rhamnosus NX-2 have uric acid reducing effects on a zebrafish high-uric-acid model, and can inhibit the activity of xanthine oxidase in the body of a high-uric-acid zebrafish. Thelactobacillus rhamnosus NX-2 disclosed by the invention has a huge potential application prospect in the aspect of preparing medicines for treating and / or preventing hyperuricemia.

The invention relates to an application of Graveobioside A in the preparation of drugs or healthcare food for preventing hyperuricemia and gout. The invention also provides a drug or healthcare food for treating hyperuricemia and gout. Graveobioside A is the active component and is mixed with a proper amount of pharmaceutical carrier or excipient to prepare preparations. Graveobioside A can prominently reduce uric acid in serum of an oteracil potassium caused hyperuricemia model mouse, reduces the activity of xanthine oxidase at different levels, and prominently inhibit the arthritis of mouse. Graveobioside A can treat and prevent hyperuricemia and gout and can be used to prepare drugs or healthcare food for preventing hyperuricemia and gout.

The invention relates to the field of microorganisms, and particularly relates to Lactobacillus gasseri LG08 with a uric acid degradation effect and application thereof. The Lactobacillus gasseri LG08is preserved in the China General Microbiological Culture Collection Center (CGMCC) in July 18, 2018, with the preservation number being CGMCC No. 16131, and is classified and named as Lactobacillusgasseri, with the preservation address being the Institute of Microbiology, Chinese Academy of Sciences, No.3, Academy No.1, Beichen West Road, Chaoyang District, Beijing. The Lactobacillus gasseri LG08 has an excellent nucleoside and nucleotide degradation capability, can decompose most precursors for uric acid synthesis, reduce the body absorption of precursors for uric acid synthesis and directly and efficiently decompose uric acid in intestinal tracts, and can further inhibit the generation of uric acid and relieve inflammation and other side reactions by reducing the serum endotoxin leveland inhibiting the xanthine oxidase activity.

The invention relates to a drug for treating purine metabolic disorder disease, provides a flavonoids compound represented by the formula (I) and a modified derivative thereof, and a use in inhibition of xanthine oxidase activity and promotion of uric acid excretion function, wherein R1, R2 and R3 independently represent -H or monosaccharide residues, and R4 represents -H or -OH. In particular, the drug is used for treating purine metabolic disorder disease, and can be used for treating hyperuricemia and related diseases and reducing a individual serum UA level; the drug is used for treating hyperuricemia; the drug is used for treating the related diseases, such as for treating gouty arthritis and arthrophlogosis caused by hyperuricemia, and for treating chronic interstitial nephritis, kidney stones and the like caused by hyperuricemia. The drug has the advantages of natural chemical structure, safety, low toxicity, rapid curative effect and fewer side effects. (I).

The invention provides an allopurinol derivative as shown in Formula I, and a preparation method and application thereof. Tumor growth can be effectively suppressed by the allopurinol derivative provided by the invention, the activity of the allopurinol derivative is equivalent to that of 17-AGG (17-allylamide-17-demethoxygeldanamycin) to which phase III clinical trial is performed, and the allopurinol derivative has a good antitumor effect. The activity of xanthine oxidase can be effectively suppressed by the allopurinol derivative, and the allopurinol derivative can be used for treating gout and provides a new drug choice for clinically treating cancer and gout. Additionally, the preparation method of the compound provided by the invention has the advantages of simplicity, lower cost, high yield and good industrial application prospect.

The invention discloses lactobacillus fermentum for preventing and treating hyperuricemia as well as a composition and application thereof, wherein the lactobacillus fermentum GF1800 for preventing and treating hyperuricemia has the preservation number of CCTCC NO:M 2021984. The lactobacillus fermentum GF1800 is high in biological activity and strong in acid production capacity, can effectively inhibit the activity of pathogenic microorganisms and xanthine oxidase, can tolerate gastric acid and cholate, has a remarkable degradation effect on nucleoside substances, uric acid, cholesterol, nitrite and the like, can efficiently inhibit intake of exogenous uric acid and increase of endogenous uric acid, can obviously reduce the blood uric acid level of hyperuricemia, and meanwhile, improves intestinal and kidney structural injury and inflammatory response. The invention further discloses a composition containing the lactobacillus fermentum GF1800 and a strain metabolite and postbiotics of the lactobacillus fermentum GF1800 and an application of the lactobacillus fermentum GF1800 and the postbiotics of the lactobacillus fermentum GF1800 to preparation of functional food or medicine for preventing and treating hyperuricemia or / and gout, degrading nucleoside, inhibiting xanthine oxidase, reducing cholesterol, degrading nitrite and inhibiting pathogenic bacteria.

The invention provides a medicine for reducing the uric acid. The medicine comprises the following components in percent by weight: 10%-40% of catechinic acid, 10%-20% of tea pigment, 10%-20% of tea compound sugar, 5%-20% of theanine, 5%-20% of vitamin C, 10%-30% of procyanidine. The medicine provided by the invention has the advantages that the uric acid is reduced by multiple aspects of inhibiting the activity of xanthine oxidase, directly decomposing the uric acid, improving the kidney function, promoting the excretion of uric acid and protecting the blood vessels and the like, and the harm to the health of a human body is eliminated. Compared with the traditional medicine for reducing the uric acid, the medicine provided by the invention has the beneficial effects that except the function of reducing the uric acid, the effect of inhibiting the activity of the xanthine oxidase is also obviously improved, the blood fat and the kidney function are also obviously improved and no side effect is caused.

The invention relates to a traditional herbal medicine-perilla leaf and a novel application of a traditional Chinese medicine composition of the perilla leaf. Through a mechanism of inhibiting xanthine oxidase activity and a mechanism of promoting uric acid to be discharged from urine, the concentration of uric acid in the blood of a body is reduced and the purposes of reducing uric acid and treating gout are achieved, so that perilla leaf extract and a traditional Chinese medicine composition of the perilla leaf extract can be applied to the preparation of drugs or foods used for preventing and treating the disease such as hyperuricemia, gout or the like. The perilla leaf extract and other traditional herbal medicines in the composition can be subjected to heating extraction by using water or hydrous ethanol as a solvent, the extraction is performed for 1-3 times, medicine residues are removed, the solvent is removed by reduced pressure concentration, powder is obtained through spray drying or freeze drying, and auxiliary materials are added to prepare a traditional Chinese medicine preparation or a food, particularly, a dosage form such as capsules, tablets, oral solutions, solid beverages or the like.

The invention provides a pharmaceutical composition for treating gout. The pharmaceutical composition consists of, by weight, pharmaceutical raw materials including butyl phthalide 25-35 parts, sedenenolide 15-25 parts and neocnidilide 40-55 parts. The invention further provides application of the pharmaceutical composition and phthalide compounds, namely the butyl phthalide, the sedenenolide and the neocnidilide in preparation of drugs for treating the gout. The pharmaceutical composition has the advantages that the pharmaceutical composition has the effect of promoting uric acid excretion and abirritation, three phthalide compounds, namely the butyl phthalide, the sedenenolide and the neocnidilide have certain xanthine oxidase inhibiting activity, and a novel source is provided for preparation of the drugs for inhibiting the xanthine oxidase activity or preventing and treating the gout.

The invention relates to a dehydrogenated silibinin substituted by meta-chlorobenzene formoxyl, a preparation method and pharmaceutical applications thereof, in particular to a preparation method and applications of 2,3-dehydrogenated silibinin substituted by 23-site meta-chlorobenzene formoxyl. The compound has applications of inhibiting activity of production of lipid superoxide induced by free radical and can be expectedly used for preparing medicine for prevention and treatment of acute and chronic liver damage, hepatitis and cerebral atherosclerosis which are caused by the lipid superoxide. The compound further shows very strong resistance for PC12 cell damage caused by free radical and can be expectedly developed into medicine for protecting cranial nerve from oxidation and preventing and treating senile dementia. Besides, the compound has strong xanthine oxidase activity inhibition and can be expectedly developed into medicine for preventing and treating diseases caused by xanthine oxidase.

The invention discloses medicine application of fructus teminaliae billaricae extract and particularly relates to application of fructus teminaliae billaricae extract and fructus teminaliae billaricae polyphenol in hyperuricemia medicine preparing. The fructus teminaliae billaricae extract and the fructus teminaliae billaricae polyphenol have the effect of xanthine oxidase activity restraining, uric acid concentration in hyperuricemia model mouse blood can be effectively lowered, the effect of hyperuricemia treating is achieved, and meanwhile the good treating effect is achieved on metabolic diseases related to hyperuricemia, namely gout.

The invention provides an effective part of perilla leaf resisting hyperuricemia and a preparation method and application thereof. The effective part takes the perilla leaf as a raw material, and is prepared by the steps of extracting with water, concentrating, ethanol precipitation, reducing pressure, recycling ethanol and obtaining an extractive; performing liquid-liquid partition of n-butyl alcohol and water on the extractive to obtain the separated part of the n-butyl alcohol; purifying the separated part of the n-butyl alcohol by macroporous resin to obtain the effective part of perilla leaf. The sum of the weight of caffeic acid, caffeic acid vinyl ester, rosmarinic acid and methyl rosmarinate accounts for 50 to 70 percent of the effective part, and the effective part contains 5 to 10 percent of scutellarin. A modern separation method and pharmacological activity screening are combined to determine the best effective part, so that the ingredient of the obtained effective part is more clear, the content of the active components is high; the result of experiment in vitro and vivo shows that the effective part of perilla leaf resisting hyperuricemia can inhabit the xanthine oxidase activity to achieve the effect of reducing trioxypurine.

The invention discloses a medicine for curing podagra, which is prepared by the raw materials with the weight proportions as follows: 15-25 parts of giant knotweed rhizome, 8-15 parts of salvia miltiorrhiza, 6-12 parts of rheum officinale, 12-17 parts of cuttlebone, 12-17 parts of isatis root, 12-17 parts of greater bunet root, 10-14 parts of herba scutellariae barbatae and 6-15 parts of radix bupleuri. The medicine for curing podagra provided by the invention has obvious effects on anti-inflammation and abirritation, can obviously lower the blood uric acid content and the activity of xanthine oxidase in livers, also can protect kidney and improve the organism condition, has excellent therapeutic effect on podagra; the therapeutic effect is excellent, the adverse reaction is little, the toxic side effect is not obvious, and the medicine is obviously better than the anti-podagra medicines clinically used at present.

The invention discloses lactobacillus rhamnosus CCFM1131 for relieving hyperuricemia, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus CCFM1131 can reduce the serum uric acid level of a hyperuricemia mouse, inhibit the xanthine oxidase (XOD) activity of serum and the liver, and reduce the occurrence of hyperuricemia and gout; the lactobacillus rhamnosus CCFM1131 can be used for down-regulating serum blood sugar, down-regulating serum total triglyceride (TG), down-regulating serum total cholesterol (TC) level and inhibiting serum alkaline phosphatase (ALP) activity; in addition, the lactobacillus rhamnosus CCFM1131 can promote the expression of the ileum uric acid transporter ABCG2. Besides, the lactobacillus rhamnosus CCFM1131 can tolerate gastrointestinaltract environment, can be used for preparing functional microbial inoculants, foods and medicines for relieving hyperuricemia and gout, and has a wide application prospect.

The invention discloses the application of a flos chrysanthemi indici extract. Linarin is contained in the flos chrysanthemi indici extract, the mass percent of the linarin is not smaller than 50 percent, the application of the flos chrysanthemi indici extract is as follows: the flos chrysanthemi indici extract is used for preventing or curing hyperuricemia. According to the invention, through the combination of the linarin contained in the flos chrysanthemi indici extract, the characteristic of lowering xanthine oxidase activity can be achieved, and the flos chrysanthemi indici extract can be used for preventing or curing hyperuricemia, can remarkably lower the serum uric acid level of a model rat, can lower the levels of serum creatinine and urea nitrogen, has the advantages of easiness in component separation, controllability in quality, low additive dose, remarkable effects and the like, and has a great and profound significance in improving human health.

The invention discloses B cell epitope for xanthine oxidase and an antigen peptide containing the epitope. The antigen peptide is prepared by the following steps: B cell epitope for xanthine oxidase is connected to a linear B cell epitope FEYQD which is at a membrane-proximal region of insulinoma-associated protein-2 by a flexible peptide in a series connection, and a terminal is connected to a N terminal of Th2 auxiliary epitope P2 of P277 by a flexible peptide in a series connection. Serum which is obtained by immunization of mice with the antigen peptide is detected by Western blot, results show that an antibody which is specifically combined with xanthine oxidase is generated, and the antigen peptide is used for detecting xanthine oxidase; serum of the mice which are immunized by the antigen peptide can be used for inhibiting exogenous activity of xanthine oxidase, the difference between the inhibition rate of xanthine oxidase and the inhibition rate of allopurinol is not substantial (P>0.5), and the serum can be used for preparing xanthine oxidase inhibitor; the antigen peptide is used for treating gout, hepatopathy, nephrosis, atherosclerotic, diabetes, senile dementia, eye diseases, cardiovascular diseases, and other diseases due to xanthine oxidase abnormity, uric acid abnormity and oxidative stress disorder with important theoretical values and wide application prospects.

The invention relates to scutellaprostin compounds, methods for preparing the same and pharmaceutical uses of the same. Particularly, the invention relates to preparation methods and pharmaceutical uses of A cyclo-dioxane scutellaprostin compounds capable of inhibiting the activities of xanthine oxidase, protecting brain nerve cells from oxidative damages and preventing and treating senile dementia. The compounds have strong inhibition effect on the activities of the xanthine oxidase and are expected to be used to prepare drugs or pharmaceutical compositions for preventing and treating diseases such as gout caused by the xanthine oxidase. The compounds have strong anti-oxidative damage and protective effects on PC12 cells simulating brain nerve cells and are expected to be used to prepare drugs or pharmaceutical compositions for protecting brain nerves, preventing aging and preventing and treating senile dementia.

The invention relates to a series of lignin flavonoid compounds as well as a preparation method and drug use thereof, in particular to a preparation method of a series of beta-cyclodioxane lignin flavonoild compounds and use thereof for preparing antioxidant drugs. The compounds have strong activity of inhibiting xanthine oxidase, and can be expected to be developed into drugs for preventing and treating gout diseases resulting from the xanthine oxidase. The compounds also exhibit strong effects of protecting against PC12 cell injury resulting from free radicals, and can be expected to be developed into drugs for preventing and treating senile dementia. The compounds also have the effects of protecting against free radicals in vitro, protecting hepatic cells and relieving injury resulting from hydrogen peroxide, thus being capable of being expected to be developed into drugs for treating various diseases resulting from the free radicals, especially the use of drugs for preventing and treating liver injury.

Disclosed is a method for alleviating the oxidative impairment of vascular function by inhibiting the activity of xanthine oxidase, or active forms thereof. Xanthine oxidase levels have been shown to be increased by a variety of conditions, including sickle cell disease. In the present disclosure, allopurinol is used to inhibit xanthine oxidase activity. As a result of the inhibition of xanthine oxidase, .NO levels in a subject can be maintained. In addition to sickle cell disease, allopurinol inhibition of xanthine oxidase may be used to treat other conditions, including, but not limited to, respiratory distress, kidney disease, liver disease, ischemia-reperfusion injury, organ transplant, sepsis, burns, viral infections and hemorrhagic shock.

The invention discloses a preparation method for low-purine edible fungus vinegar rich in amino acid and vitamin D. The method comprises the steps that edible fungi and arthrobacter ultrasound breaking liquid are prepared; the arthrobacter (ATCC21606) breaking liquid, 5% saccharose and active dry yeast are added for alcoholic fermentation, and acetic fermentation, plate-frame pressure filtration and preparation are performed with mixed acetic acid bacteria (an acetic acid bacterium AS1.01 and Gluconacetobacter hansenii, ATCC 23769). The preparation method is characterized in that the arthrobacter breaking liquid which is high in xanthine oxidase activity is added before alcoholic fermentation is performed, acetic fermentation is performed with the Gluconacetobacter (hansenii, ATCC 23769) which can generate fiber, intermittent fermentation with standing and stirring performed alternately is adopted, vinegar liquid is sterilized through plate-frame pressure filtration, and therefore the obtained fungus vinegar is rich in amino nitrogen, safe in purine content and high in vitamin D content.

The invention discloses a mutant xanthine dehydrogenase and applications thereof. The mutant xanthine dehydrogenase is obtained through any of the following mutations of a wild mutant xanthine dehydrogenase: 1) a polypeptide fragment with 15 amino acids with the length being made up of QDISAVCYKLSKRFE is inserted between D358 and E359 sites of an alpha subunit of the wild mutant xanthine dehydrogenase; 2) an F270L mutation is carried out on the alpha subunit of the wild mutant xanthine dehydrogenase; and 3) an S362A mutation is carried out on the alpha subunit of the wild mutant xanthine dehydrogenase. Xanthine oxidase activity of the mutant xanthine dehydrogenase is significantly enhanced. Compared with the wild mutant xanthine dehydrogenase, the activity of catalytic oxidation of a xanthine substrate is increased by 2125 times, 63 times and 122 times by using oxygen in air as an electron acceptor, and so the production cost can be reduced, and the mutant xanthine dehydrogenase is more suitable for industrial production applications.

The invention discloses a method for preparing a functional beverage for preventing and relieving gout. Artemisia selengensis leaves and old stems and white granulated sugar are used as main raw materials, the method comprises the following production technologies of removing grassy taste, performing superhigh pressure homogenizing, performing squeezing to obtain juice, performing compounding, performing sterilizing and the like, and a superhigh pressure homogenizing technique is used for treating the artemisia selengensis leaves and old stems so as to prepare the functional beverage for preventing and relieving gout, so that the dissolution rate of flavonoids in artemisia selengensis can be increased by 120% or above, and the content of effective components in products is guaranteed. A treatment technique that fresh artemisia selengensis is used for removing the grassy taste is adopted, so that the grassy taste of the fresh artemisia selengensis is effectively removed, and the flavor and the clarity of the product are improved. According to the functional beverage, fruits and vegetables, namely the artemisia selengensis leaves and old stems, which are common in daily life of people and have the function of restraining the activity of xanthine oxidase, are used as main raw materials for preparing the functional beverage for preventing and relieving gout, so that the activity of the xanthine oxidase is effectively reduced, the attack rate of the gout is prevented and reduced, and the functional beverage does not have any side effect.

The invention provides an allopurinol derivative shown in a formula I and a method for preparing the same. The allopurinol derivative can effectively inhibit tumor growth, and has a good antitumor effect; the allopurinol derivative can also effectively inhibit xanthine oxidase activity, can be used for gout treatment, and provides a new pharmaceutical option for clinically treating cancer and gout; and moreover, the preparation method of the compound is simple, is lower in cost, and has high yield and a good industrial application prospect.

The invention relates to novel application of garcinia mangostana L pericarp extract in prevention and treatment of hyperuricemia and gout. Researches find that the garcinia mangostana L pericarp extract is capable of in-vitro inhibiting activities of xanthine oxidase, and IC50 of the garcinia mangostana L pericarp extract is 31.39ml / L. in vivo studies show that the garcinia mangostana L pericarpextract has a strong uric acid lowering effect, by feeding 20mg / kg of the garcinia mangostana L pericarp extract to a mouse with oteracil potassium induced hyperuricemia intragastrically, the serum uric acid level of the mouse can be obviously lowered, which means the uric acid lowering effect of the garcinia mangostana L pericarp extract is related to inhibition of the xanthine oxidase activities, and generation of the uric acid is inhibited. By feeding 2.0g / kg of the garcinia mangostana L pericarp extract to the mouse intragastrically, no animal dies, and no obvious toxic and side effect isfound, so that the garcinia mangostana L pericarp extract can be used for preparing oral medicaments for treating the gout and the hyperuricemia and medicament and health care products for diseases related to the hyperuricemia.

The invention discloses a composition for reducing blood uric acid of hyperuricemia. The composition is prepared from the following ingredients in parts by weight: 25 to 100 parts of orange extracts,50 to 200 parts of grape seed extracts, 5 to 20 parts of vitamin E, 2.5 to 10 parts of vitamin B6, 5 to 20 parts of nicotinic acid, 50 to 200 parts of zinc gluconate and 500 to 2000 parts of potassiumcitrate. The animal effect evaluation result shows that the composition provided by the invention can obviously improve the urine pH of a rat with hyperuricemia; the 24h urine discharge quantity is obviously improved; the serum total anti-oxidization capability is improved; the lipid peroxide content is obviously reduced; the serum xanthine oxidase activity is reduced; the blood uric acid level is obviously reduced. The animal experiment result shows that when a proper quantity of the composition is supplied to the model rat with the hyperuricemia, the body anti-oxidization capability can beobviously improved; the blood uric acid is reduced.